Pure Global
NCT06366243

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

A Phase 1, Open-Label, Fixed-Sequence Trial to Evaluate the Effect of Esomeprazole and Gastric pH-Altering on the Pharmacokinetics of Emraclidine in Healthy Adult Participants
Cerevel Therapeutics, LLC·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
Emraclidine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Cerevel Therapeutics, LLC
Timeline & enrollment
Phase
Phase 1
Start date
May 10, 2024
End date
Jun 24, 2024
Enrollment
20 participants
Primary outcome

Maximum Observed Plasma Concentration (Cmax) of Emraclidine,Time to Maximum (Peak) Plasma Concentration (Tmax) of Emraclidine,Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-t) of Emraclidine,Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Emraclidine

Summary

The primary purpose of this study is to evaluate the potential of gastric pH-dependent
 drug-drug interaction effect of esomeprazole, a proton pump inhibitor (PPI), on the
 pharmacokinetics (PK) of emraclidine in healthy adult participants.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06366243
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06366243 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cerevel Therapeutics, LLC and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.